Back to top
Search by company, common medicine name, or title of Risk Minimisation Material
This risk minimisation material is a condition of the marketing authorisation. This card should be provided to patients receiving treatment with infliximab. It gives important safety information for the patient and allow important details of their treatment to be recorded
This Patient Reminder Card contains important safety information that you need to be aware of before and during treatment with Remsima.
This Patient Reminder Card contains important safety information that you need to be aware of before and during treatment with Remsima.
This Patient Reminder Card contains important safety information that you need to be aware of before and during treatment with Remsima.
For Healthcare Professionals
Replagal HCP Guide
The safe use of lenalidomide is of paramount importance. Adverse events (and cases of suspected or confirmed pregnancy or foetal exposure) should be reported to BMS. You can also report the event online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
For Healthcare Professionals
This brochure contains the information needed for prescribing and dispensing of lenalidomide, including information about the Pregnancy Prevention Programme. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient. Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.
This brochure should be given to patients receiving treatment with lenalidomide, as it provides important information about the lenalidomide Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking lenalidomide and how to report side effects.
For Healthcare Professionals
This Treatment Initiation Form must be completed for each male patient prior to the initiation of their lenalidomide treatment. It is mandatory that male patients receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.
This card should be given to all patient as it reminds patients of the key educational information and risks of treatment with lenalidomide.
For Healthcare Professionals
This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense lenalidomide. In order to ensure that the actions to minimise the risk of foetal exposure are carried out for all patients, dispensing of lenalidomide will only be allowed from pharmacies registered with BMS.
The safe use of lenalidomide is of paramount importance. Any cases of suspected or confirmed pregnancy or foetal exposure should be immediately reported to BMS. You can also report the event via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Use this form to provide information about the outcome of pregnancy.
The safe use of lenalidomide is of paramount importance. Any cases of suspected or confirmed pregnancy or foetal exposure should be immediately reported to BMS. You can also report the event via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
A newly completed Prescription Authorisation Form must accompany each lenalidomide prescription to confirm that the patient has been counselled about the teratogenic risk of lenalidomide and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.
This checklist is to assist you with counselling a patient before they commence lenalidomide treatment in order to ensure it is used safely and correctly. The Algorithm provides high level steps for prescribing and dispensing of lenalidomide.
This Treatment Initiation Form must be completed for each woman of childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.
This Treatment Initiation Form must be completed for each woman of non-childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.
For Healthcare Professionals
This pack contains the all the additional Risk Minimisation Materials required to prescribe and dispense lenalidomide. It also contains important reporting forms, information for patients, prescribing tools, and the Pharmacy Registration Form. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient.
For Healthcare Professionals
Rinvoq Healthcare Professional Guide - for HCP's
For Healthcare Professionals
A healthcare professional card highlighting the route of administration for Rixathon Healthcare Professional
For Healthcare Professionals
This guide is intended to review key facts and important safety information about rituximab in non-oncology diseases and to provide important patient counselling information to assist healthcare professionals in caring for patients receiving rituximab therapy.
The information provided in this booklet should be discussed with patients by their healthcare professional during Rixathon(rituximab) treatment.
For Healthcare Professionals
This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan
This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan
For Healthcare Professionals
This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
Non-promotional educational materials of Immunological Assessments for the Healthcare Professional
For Healthcare Professionals
Provides guidance on the route of administration (intravenous only), management, monitoring and safety considerations related to the risk management plan.
Provides help to patients to understand the risks associated with Ruxience and reminds them to seek immediate medical attention if they experience any of the listed signs and symptoms.
Provides information to patients on the risks, signs and symptoms of infection and the need to contact their doctor immediately if they experience them.
For Healthcare Professionals
Information to provide guidance on Dosing and Administration of Rybrevant including Dosing Schedules and Modifications.
Are you a healthcare professional?
Skip to main content